Sebastian Stasik

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.

Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 20, 2026

PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.

PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.

Journal: Annals of hematology

Published: October 08, 2025

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Journal: Leukemia

Published: August 15, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.

The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.

Journal: British journal of haematology

Published: November 18, 2024

Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML.

Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML.

Journal: HemaSphere

Published: October 23, 2024

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.

Journal: Acta neuropathologica communications

Published: May 06, 2024

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Journal: Blood advances

Published: April 03, 2024

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence.

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence.

Journal: NPJ digital medicine

Published: November 12, 2023

Prognostic impact of CEBPA mutational subgroups in adult AML.

Prognostic impact of CEBPA mutational subgroups in adult AML.

Journal: Leukemia

Published: October 30, 2023

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.

Journal: Leukemia

Published: July 17, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026